You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Unicondylar Resurfacing in an Ovine Osteoarthritis Disease Model
SBC: Cytex Therapeutics, Inc. Topic: NIAMSAbstractThe treatment of large cartilage lesions is a difficult clinical problem for which there are few good solutionsLeft untreatedthese lesions tend to degenerate to chronic pain and osteoarthritisOAultimately requiring a total joint replacementFor patients suffering from knee OAandin particularunicompartmental OAunicondylar knee arthroplastyUKAis an available first line treatment option that p ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Development of user-friendly fluorescence based assays for marine toxins
SBC: SEATOX RESEARCH INC Topic: 113ABSTRACTHarmful algal bloomsHABsare becoming frequent occurrences off the coasts of the United Stateswith specific instances in the coastal waters of the west coastthe Gulf of Mexicoand the Pacific OceanHistoricallyHABs have been associated with fish kills and marine mammal mortalitieshowevertheir effects on human health and economic loss due to HAB contamination of seafood are becoming more preva ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Microfluidic Nitric Oxide Sensor
SBC: CLINICAL SENSORS, INC. Topic: NIAIDPROJECT SUMMARY Clinical Sensors has developed a manufacturable prototype microfluidic sensor for measuring nitric oxide in whole bloodThis STTR Phase II project aims to complete several key aims necessary to commercialize this deviceincluding a clinical study where NO levels will be evaluated clinically in sepsisSepsis is the leading cause of death in non cardiac intensive care unitsICUsEach year ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
An integrative multi phenotype pipeline for drug evaluation pharmacogenomics and attribute prediction
SBC: PHENVOGEN LLC Topic: 300PROJECT SUMMARY The process of drug discovery is costly and many promising compounds fail during clinical trials By then expenses upward of $ million dollars per failed drug may have incurred and these financial risks hamper research efforts and ultimately reduce the availability of treatment options In this research proposal we are using systematic approaches to map the relationships be ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Oligonucleotide Inhibition for cardiac regeneration in Ischemia
SBC: JAAN BIOTHERAPEUTICS LLC Topic: NHLBIPROJECT SUMMARY Ischemic heart disease IHD is the single largest cause of death worldwide A heart attack or myocardial infarction MI results from limitation of coronary blood flow to the heart causing ischemia and ultimately irreversible death of cardiomyocytes The size of a myocardial infarct correlates with the degree of deterioration of heart function compromise of contractile reserve ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Peripheral FAAH as a target for novel analgesics
SBC: Anteana Therapeutics Inc Topic: NIDADESCRIPTIONprovided by applicantPain management is a significant unmet medical needAnandamide is an endocannabinoid mediator that plays important roles in the regulation of painPrevious work has shown that endocannabinoid receptors located outside the central nervous systemCNSexert a powerful regulatory control over pain initiationThe biological actions of anandamide are stopped by the enzymefatty ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Novel Small Molecule Macrophage Inhibitors for the Treatment of Retinal Diseases
SBC: Eyedesis Biosciences, LLC Topic: NPROJECT SUMMARY ABSTRACT Persistent disease activity PDA in spite of anti vascular endothelial growth factor VEGF therapy remains a significant clinical unmet need for patients with neovascular age related macular degeneration NVAMD The purpose of this STTR Phase I grant application is to develop novel therapies that will be effective for the treatment of PDA associated with NVAMD The cu ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
A novel anti gonorrhea immunotherapeutic
SBC: Planet Biotechnology Incorporated Topic: NIAIDAntimicrobial resistance is a major public health problem worldwide Neisseria gonorrhoeae Ng the causative agent of the sexually transmitted infection gonorrhea has become multidrug resistant and has achieved superbug status Novel therapeutics against Ng are urgently needed Complement C is a key arm of innate immune defenses A mechanism used by several pathogens including Ng to esca ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Towards a New Generation of Glycoengineered Pneumococcal Bioconjugate Vaccines
SBC: VaxNewMO Topic: NIAIDPROJECT SUMMARY Pneumococcal pneumonia remains the leading cause of bacterial pneumonia in both children under years of age and adults over years of age The standard preventative therapy is the conjugate vaccine Prevnar which consists of an immunogenic carrier protein covalently attached to one of thirteen pneumococcal capsular polysaccharides Although Prevnar has significantly red ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Personalized Neural Stem Cell Therapy for Cancer
SBC: Falcon Therapeutics, Inc. Topic: NCATSProject Summary Abstract Glioblastoma GBM is the most common primary brain tumor and one of the deadliest forms of cancer Standard surgery chemotherapy and radiation fail to eliminate the infiltrative invasive cancer cells Median survival remains only months Drugs that seek out the disseminated GBM cells behind the blood brain barrier will prevent the inevitable recurrence in patients ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health